Skip to main content
. 2022 Feb 12;13(5):1413–1447. doi: 10.1016/j.jcmgh.2022.02.006

Figure 14.

Figure 14

The effects of HNRNPM-specific ASO for HCC in vivo and in vitro.A, The expression of HNRNPM was significantly correlated with MBD2a. B, The IC50 of ASO-2 for MHCC97H cells. C, The protein expression of HNRNPM, MBD2a, FZD3, OCT4, SOX2, and β-catenin related assays when treated with ASO-2 in HCC cells. Data were from 3 independent experiments. ∗P < .05 by the Student t test. D, The CSC markers expression by ASO treatment. E, The CCK-8 experiment when treated with HNRNPM-specific ASO in MHCC97H cells. F, Sphere formation and limiting dilution assays when treated with HNRNPM-specific ASO in MHCC97H cells. Data were from 3 independent experiments. ∗P < .05 by the Student t test. G, Limiting dilution assays when treated with HNRNPM-specific ASO in MHCC97H cells. H, Colony formation assay when treated with HNRNPM-specific ASO in MHCC97H cells. Data were from 3 independent experiments. ∗P < .05. I-J, Invasion assay (I) and cell migration (J) and when treated with HNRNPM-specific ASO in MHCC97H cells. Data were from 3 independent experiments. ∗P < .05 by the Student t test. K, The HCC cell apoptosis changes by ASO treatment. Data were from 3 experiments. ∗∗P < .01 by the Student t test. L, The schematic diagram of ASO-2 treating nude mice when inoculating the tumor cells. M, The effects of HNRNPM-specific ASO when treated ASO I.P by 25 mg/kg (n = 5). ∗∗∗P < .001 by the Student t test. N,. The HNRNPM expression in tumors when treating HNRNPM-ASO by IHC experiments.